Catalyst Pharmaceuticals Inc (CPRX)
16.53
-0.19
(-1.14%)
USD |
NASDAQ |
Mar 30, 10:36
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.746B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 106.2% |
| Valuation | |
| PE Ratio | 22.34 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 8.580 |
| Price to Book Value | 5.813 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 66.55% |
News
Headline
Wire
Time (ET)
Yahoo
03/27 07:12
Yahoo
03/22 09:55
MT Newswires
03/16 08:22
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/11/2023* | 08:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/10/2023* | -- | Results | Q1 2023 | -- | 0.31 | -- | |
| 03/16/2023 | 08:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 03/15/2023 | -- | Results | Q4 2022 | 0.22 | 0.20 | 11.86% | |
| 11/10/2022 | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/09/2022 | -- | Results | Q3 2022 | 0.24 | 0.19 | 23.77% | |
| 08/10/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/09/2022 | -- | Results | Q2 2022 | 0.20 | 0.17 | 21.21% |
*Estimated Date/Time
Earnings
Profile
| Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. |
| URL | https://www.catalystpharma.com |
| Investor Relations URL | https://ir.catalystpharma.com/ |
| HQ State/Province | Florida |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 10, 2023 (est.) |
| Last Earnings Release | Mar. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 29, 2023.
Fundamentals
| Revenue (TTM) | 214.20M |
| Total Expenses (TTM) | 112.36M |
| Net Income (TTM) | 83.08M |
| Total Assets (Quarterly) | 375.63M |
| Total Liabilities (Quarterly) | 75.21M |
| Shareholders Equity (Quarterly) | 300.42M |
| Cash from Operations (TTM) | 116.05M |
| Cash from Investing (TTM) | 9.209M |
| Cash from Financing (TTM) | 1.694M |
Ratings
Profile
| Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. |
| URL | https://www.catalystpharma.com |
| Investor Relations URL | https://ir.catalystpharma.com/ |
| HQ State/Province | Florida |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 10, 2023 (est.) |
| Last Earnings Release | Mar. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| TGFRX | 1.360M USD | 8.79% |
| PBE | 7.558M USD | 3.06% |
| YOVAX | 763000.0 USD | 2.11% |
| PTH | 3.522M USD | 1.95% |
| PSCH | 4.678M USD | 1.63% |
| BPLEX | 921059.0 USD | 1.30% |
| XBI | 71.56M USD | 1.11% |
| HIL269 | 4.862M USD | 1.09% |
| IMPAX | 829541.0 USD | 1.03% |
| DWAS | 4.597M USD | 0.92% |
| QSMNX | 1.053M USD | 0.91% |
| LABU | 7.444M USD | 0.85% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| CPRX Tweets |